Cognitive performance in people with Parkinson's disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapy
Language English Country Great Britain, England Media print
Document type Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial
PubMed
15613141
DOI
10.1111/j.1468-1331.2004.00966.x
PII: ENE966
Knihovny.cz E-resources
- MeSH
- Dopamine Agonists therapeutic use MeSH
- Analysis of Variance MeSH
- Depression complications drug therapy psychology MeSH
- Cognition Disorders complications drug therapy psychology MeSH
- Drug Therapy, Combination MeSH
- Levodopa therapeutic use MeSH
- Middle Aged MeSH
- Humans MeSH
- Statistics, Nonparametric MeSH
- Parkinson Disease complications drug therapy psychology MeSH
- Prospective Studies MeSH
- Aged MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Multicenter Study MeSH
- Randomized Controlled Trial MeSH
- Comparative Study MeSH
- Names of Substances
- Dopamine Agonists MeSH
- Levodopa MeSH
In a randomized prospective multi-centre study, we evaluated the cognitive performances of a group of 41 non-demented patients, all with advanced Parkinson's disease (PD) and a current depressive episode, in whom the effects of pramipexole (PPX) and pergolide (PRG) in an add-on to l-dopa therapy were also studied and published with regard to motor symptoms of PD, motor complications and depression. The Trail Making Test, the Stroop test and four subtests (arithmetic, picture completion, digit symbols and similarities) of the Wechsler Adult Intelligence Scale-Revised were performed prior to and 8 months after the administration of either PPX or PRG. We found no statistically significant difference between the two tested drugs or between the first and the last visit in any of the above-listed neuropsychological tests. All patients' motor outcomes significantly improved and we conclusively demonstrated the anti-depressive effect of PPX. The dissociation of dopaminomimetic effects on the different tested domains indicates that there are different pathological mechanisms of cognitive, motor and affective disturbances in advanced PD patients. In our non-demented group of fluctuating depressed PD subjects, both PPX and PRG administration in combination with l-dopa were safe in terms of the effect on cognitive performance.
References provided by Crossref.org
Levodopa may modulate specific speech impairment in Parkinson's disease: an fMRI study
The reduction of hippocampal volume in Parkinson's disease
